AstraZeneca looks to CRISPR to boost success ratesBetween 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below Share XAstraZeneca looks to CRISPR to boost success rateshttps://pharmaphorum.com/views-and-analysis/astrazeneca-crispr-boost-success-rates/
Merck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKMerck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in Share XMerck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKhttps://pharmaphorum.com/r-d/views-analysis-r-d/merck-cancer-blockbuster-keytruda-funds-rare-disease/
Dreaming big with small moleculesClovis Oncology has gone from a small biotech to a pharma company with a cutting-edge cancer drug approved Share XDreaming big with small moleculeshttps://pharmaphorum.com/views-analysis-oncology/dreaming-big-small-molecules/
Has the NHS joined the biosimilars revolution?Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul Share XHas the NHS joined the biosimilars revolution?https://pharmaphorum.com/oncology/nhs-joined-biosimilar-revolution/
How the NHS got ahead of the curve with CAR-TThe UK’s pharma industry has welcomed the NHS’ fast adoption of the latest CAR-T cancer therapies. Richard Staines Share XHow the NHS got ahead of the curve with CAR-Thttps://pharmaphorum.com/views-analysis-oncology/nhs-got-ahead-curve-car-t/
Merck KGaA’s bold new approach to cancer immunotherapyGermany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer Share XMerck KGaA’s bold new approach to cancer immunotherapyhttps://pharmaphorum.com/views-analysis-oncology/merck-kgaas-bold-new-approach-to-cancer-immunotherapy/
Quality of life increasingly important in skin cancer, say doctors at this year’s ESMOThe factors a doctor should consider when choosing between therapies that could cure patients with skin cancer proved Share XQuality of life increasingly important in skin cancer, say doctors at this year’s ESMOhttps://pharmaphorum.com/views-analysis-oncology/quality-of-life-increasingly-important-in-skin-cancer-esmo/
Ahead of the curvePharma often criticises the NHS for failing to adopt the latest therapies, arguing that NICE’s technology appraisals can Share XAhead of the curvehttps://pharmaphorum.com/views-analysis-oncology/ahead-curve-car-t/
Digital health technology has the potential to transform cancer careDigital and connected health technology has real potential to transform cancer care, writes Piotr Wnuk. Start-ups are utilising Share XDigital health technology has the potential to transform cancer carehttps://pharmaphorum.com/views-analysis-oncology/digital-health-technology-has-potential-to-transform-cancer-care/
